Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours ยท Estimated delivery Aug 31 - Sep 5
Not intended for diagnostic, therapeutic, or clinical use
Recent employer surveys show: 19% of employers with 200+ employees cover GLP-1s for weight loss 43% of employers with 5,000+ employees provide coverage 64% of employers with 20,000+ employees offer coverage Large employers are increasingly viewing obesity as a chronic condition requiring long-term treatment strategies rather than short-term interventions
Eligibility and Authority You must be at least 21 years old and legally capable of entering a binding agreement
The SURMOUNT-1 Phase 3 trial published in The New England Journal of Medicine enrolled 2,539 adults with obesity and demonstrated mean body weight reduction of 20.9% at 72 weeks on tirzepatide 15mg weekly versus 3.1% placebo
Recalls & Warnings November 25, 2017 Seller of "BounceBack" Joint Supplement and Others Products Warned for Drug Claims On November 14, 2017, the FDA sent a warning letter to Mannatech Incorporated following a facility inspection that found the products BounceBack, MannaBears, ImmunoSTART, TruSHAPE, and Catalyst to be in violation of the Current Good Manufacturing
